Page 6 - Divi Lab News Today

Can consumption continue to support growth? Well soon know how strong festive demand has been

Foreign institutional investors offloaded shares worth Rs 549.37 crore, while domestic institutional investors bought Rs 595.70 crore worth of stocks on November 6, provisional data from the National Stock Exchange showed.

Get latest articles and stories on Business at LatestLY. At the opening bell, the Sensex displayed a decline of 139.89 points, starting at 64,818.80. Simultaneously, the Nifty exhibited a 33.00 point decrease, initiating trading at 19,378.75. Business News | Nifty's Opening Surge: Stock Market Defies the Morning Dip as Key Sectors Drive Optimism.

​They caution if this support is breached, there is a likelihood that the index could further decline towards the range of 19,000 to 18,900 in the coming weeks. Analysts suggest traders may want to explore potential opportunities in Reliance, HDFC Bank, IndusInd Bank, and Sun Pharma.

“I think the second half of the year will look good for any of our larger holdings. For example, we are a large shareholder in Divis Lab, in Alkyl Amines, in GMM Pfaudler, in Paushak and we are hoping the second half of the year will bring good news as the price action seems to have bottomed out. ”

Nifty and Senex jumped 1 percent on September 29. According to analysts, the ‘triple whammy’ of up-trending dollar, US bond yields and Brent crude is showing signs of easing, and if this continues, it will facilitate a recovery in markets

Pharma stocks surged nearly 10% on Friday taking Nifty Pharma index up 3%, with Glenmark Pharma seeing the largest rise of up to 9.5 percent. Heres whats fuelling the rally in Pharma stocks.

Some pharma companies, on September 29, gained as much as 10%

Nilima Motaparti, one of the wealthiest women in India with a stated net worth of over Rs 28,180 crore as of March 2023, is one such successful person. Murali Krishna Divi, who started Divi's Laboratories, is the father of Nilima Motapatri.

Khemka also says there are many reasons unbranded generics won’t work in India.